Sherlock Biosciences: Raises $80M in Series B Funding

Sherlock Biosciences Raises $80M in Series B Funding

  • Sherlock Biosciences, a Boston, MA-based biology diagnostics company, raised $80M in Series B funding.
  • The company intends to use the funds to expand products and partnerships
  • SherlockBiosciences is a company engineering biology to bring next-generation diagnostics to the point-of-need
  • Powered by CRISPR and synthetic biology, Sherlock’s proprietary engineering biology tools form the foundation of its decentralized diagnostic platform for DNA and RNA detection
  • In 2020 the company made history with the first FDA-authorized use of CRISPR technology
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

Experian Strengthens Services with Atdata Acquisition

The acquisition boosts Experian's email identity verification capabilities.Highlights: Experian has acquired Atdata, enhancing its email verification services.The deal...

Crypto.com Secures Conditional Approval for National Trust Bank Charter

The crypto exchange aims to expand its financial services in the U.S.Highlights: Crypto.com receives conditional approval for a...

PayPal Draws Takeover Interest Amid Market Changes

Bloomberg reports on potential acquisition speculations surrounding PayPal.Highlights: PayPal has caught the attention of potential buyers, according to...

Chase Accelerates Expansion with 160 New Branches by 2026

The banking giant aims to enhance accessibility for customers across the U.S.Highlights: Chase plans to open 160 new...